KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Accumulated Expenses (2018 - 2025)

Historic Accumulated Expenses for Vir Biotechnology (VIR) over the last 8 years, with Q3 2025 value amounting to $68.4 million.

  • Vir Biotechnology's Accumulated Expenses fell 2776.63% to $68.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.4 million, marking a year-over-year decrease of 2776.63%. This contributed to the annual value of $85.9 million for FY2024, which is 1760.41% down from last year.
  • Per Vir Biotechnology's latest filing, its Accumulated Expenses stood at $68.4 million for Q3 2025, which was down 2776.63% from $82.7 million recorded in Q2 2025.
  • Vir Biotechnology's 5-year Accumulated Expenses high stood at $489.1 million for Q4 2022, and its period low was $7.7 million during Q1 2022.
  • In the last 5 years, Vir Biotechnology's Accumulated Expenses had a median value of $94.7 million in 2024 and averaged $160.8 million.
  • As far as peak fluctuations go, Vir Biotechnology's Accumulated Expenses tumbled by 8901.08% in 2022, and later skyrocketed by 582106.49% in 2023.
  • Vir Biotechnology's Accumulated Expenses (Quarter) stood at $236.5 million in 2021, then skyrocketed by 106.79% to $489.1 million in 2022, then tumbled by 78.69% to $104.2 million in 2023, then fell by 17.6% to $85.9 million in 2024, then fell by 20.38% to $68.4 million in 2025.
  • Its last three reported values are $68.4 million in Q3 2025, $82.7 million for Q2 2025, and $104.1 million during Q1 2025.